Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti‐Retroviral Therapy for AIDS

Abstract:  The advent of highly active anti‐retroviral therapy (HAART) has dramatically decreased the rate of AIDS‐related mortality and significantly extended the life span of patients with AIDS. A variety of metabolic side effects are associated with these therapies, one of which is metabolic bone disease. A higher prevalence of osteopenia and osteoporosis in HIV‐infected patients receiving anti‐retroviral therapy than in patients not on therapy has now been reported in several studies. Several factors have been demonstrated to influence HIV‐associated decreases in bone mineral density (BMD), including administration of nucleoside reverse transcriptase inhibitors (NRTIs). In this article, discussion will focus on the molecular pathogenesis and treatment of HAART‐associated osteopenia and osteoporosis.

[1]  J. McDonald,et al.  Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. , 2006, AIDS research and human retroviruses.

[2]  Shi Wei,et al.  IL-1 mediates TNF-induced osteoclastogenesis. , 2005, The Journal of clinical investigation.

[3]  J. Laurence,et al.  Interactions among human immunodeficiency virus (HIV)‐1, interferon‐γ and receptor of activated NF‐κ B ligand (RANKL): implications for HIV pathogenesis , 2004 .

[4]  Michael W.-H. Wang,et al.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. , 2004, The Journal of clinical investigation.

[5]  T. Nagy,et al.  AZT enhances osteoclastogenesis and bone loss. , 2004, AIDS research and human retroviruses.

[6]  M. Šuša,et al.  Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay , 2004, Journal of Translational Medicine.

[7]  M. Välimäki,et al.  Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. , 2004, The Journal of clinical endocrinology and metabolism.

[8]  A. Cossarizza,et al.  Antiretroviral nucleoside and nucleotide analogues and mitochondria. , 2004, AIDS.

[9]  C. Baudoin,et al.  BMD Is Reduced in HIV‐Infected Men Irrespective of Treatment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  J. Laurence,et al.  Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. , 2004, Clinical and experimental immunology.

[11]  J. Choudhuri,et al.  Use of viral promoters in mammalian cell-based bioassays: How reliable? , 2004, Journal of Translational Medicine.

[12]  J. Laurence,et al.  HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk* , 2003, Journal of Biological Chemistry.

[13]  P. Tebas,et al.  Emerging bone problems in patients infected with human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Grinspoon,et al.  Weight loss and wasting in patients infected with human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Bostrom,et al.  Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management , 2003, AIDS.

[16]  M. Schambelan,et al.  Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Schambelan,et al.  Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV‐1 Infection: Recommendations of an International AIDS Society‐USA Panel , 2002, Journal of acquired immune deficiency syndromes.

[18]  J. Lenhard,et al.  Select HIV Protease Inhibitors Alter Bone and Fat Metabolismex Vivo * , 2002, The Journal of Biological Chemistry.

[19]  E. Georgiou,et al.  Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors , 2002, HIV medicine.

[20]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[21]  C. Sabin,et al.  Reduced bone mineral density in HIV-positive individuals. , 2001, AIDS.

[22]  R. Chaisson,et al.  Increasing incidence of avascular necrosis of the hip in HIV-infected patients. , 2001, Journal of acquired immune deficiency syndromes.

[23]  T. Y. Wong,et al.  Primary human immunodeficiency virus infection: heightened awareness needed. , 2001, Hong Kong medical journal = Xianggang yi xue za zhi.

[24]  P. Mantyh,et al.  Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.

[25]  J. Eisman,et al.  Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy , 2001, AIDS.

[26]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[27]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[28]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[29]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[30]  J. Papadimitriou,et al.  A critical analysis of the pharmacology of AZT and its use in AIDS. , 1999, Current medical research and opinion.

[31]  J. Bollerslev,et al.  Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  M. Tius,et al.  Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[33]  I. Fridovich,et al.  Growth in Iron-enriched Medium Partially CompensatesEscherichia coli for the Lack of Manganese and Iron Superoxide Dismutase* , 1998, The Journal of Biological Chemistry.

[34]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[35]  N. Paton,et al.  Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection , 1997, Calcified Tissue International.

[36]  P. Eiken,et al.  Effects on bone mass after eight years of hormonal replacement therapy , 1997, British journal of obstetrics and gynaecology.

[37]  A. Billiau,et al.  Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. , 1997, Journal of immunology.

[38]  S. Huang,et al.  High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. , 1997, Journal of immunology.

[39]  A. Goday,et al.  Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. , 1995, Bone.

[40]  E. de Ramón,et al.  Avascular necrosis of bone in human immunodeficiency virus infection and antiphospholipid antibodies. , 1993, The Journal of rheumatology.